AYTU BIOPHARMA, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $15M | ↓-6.5% | $-11M | ↓-1443.1% | -13.0% |
| 2025-09-30 | $14M | ↓-16.2% | $2M | ↑+33.3% | -10.8% |
| 2025-06-30 | $15M | ↑+601.7% | — | — | — |
| 2025-03-31 | $18M | ↑+31.6% | $4M | ↑+238.3% | 13.1% |
| 2024-12-31 | $16M | ↓-13.5% | $788K | ↑+458.2% | -10.4% |
| 2024-09-30 | $17M | ↓-7.0% | $1M | ↑+118.2% | -5.6% |
| 2024-06-30 | $2M | ↓-93.0% | — | — | — |
| 2024-03-31 | $14M | ↓-38.3% | $-3M | ↑+59.9% | -11.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 65 quarters
margin trajectory tells the operating-leverage storyGo deeper
AYTU Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyAYTU Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics